… Several preclinical reports dealing with anticancer DC vaccines were published since our
last Trial Watch on this topic (February 2017). Citation279 Of this abundant preclinical literature…

… trials. Obviously, this approach cannot be undertaken in the wide range of tumors for which
an intratumoral injection … with an allogeneic prostate cancer cell vaccine in patients with non-…

… vaccines to generate a pool of TAA-specific effector T cells and facilitate their infiltration into
the tumor bed. In this Trial Watch, … blockers and adoptive T-cell transfer-based approaches …

… In this Trial Watch, we review the latest preclinical and clinical progress in the development
of DC vaccines for oncological indications. Immune checkpoint blockers (ICBs) and adoptive …

… Several of these papers reported the results of recently completed clinical trials assessing
the clinical profile of DC-based vaccines in cancer patients. In particular, autologous DCs …

… As for the clinical trials listed in our previous Trial Watch dealing with this topic,Citation …
, and NCT01334047 since new knowledge about anticancer vaccines had to be taken into …

… Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a
phase I/II study in metastatic melanoma patients. Clin Cancer Res 2010; 16, 5067-78; PMID:…

… vaccine was used for different solid tumors, [15, 16] and vaccination with dendritic cells (DCs…
Antigen-presenting cell-based immunotherapies with active DCs have been documented to …

… processed by the proteasome, these proteins can give rise to antigens that are not covered
by central or peripheral tolerance and hence can be productively presented by dendritic cells …

… T cells from the tumor, or from T cell dysfunction induced by the tumor microenvironment.
Citation8 This latter could be related to dendritic cell (… dendritic cells (PDCs), which skew T cell …